AAS
ITCI

Avantax Advisory Services’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Avantax Advisory Services’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,494
Closed -$375K – 2343
2024
Q4 		$375K Sell
4,494
-24
-0.5% -$1.97K ﹤0.01% 1630
2024
Q3 		$331K Buy
4,518
+94
+2% +$7.07K ﹤0.01% 1686
2024
Q2 		$303K Buy
+4,424
New +$307K ﹤0.01% 1690

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Avantax Advisory Services's ITCI Position: Q1 2025 in Review

Avantax Advisory Services sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 4,494 shares — an estimated $375K sold.

Avantax Advisory Services first reported a position in ITCI in Q2 2024 and held it in 3 quarters. The position peaked at $375K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Avantax Advisory Services reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Avantax Advisory Services sold 4,494 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $375K.
  • Avantax Advisory Services first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 3 quarters.
  • Avantax Advisory Services's Intra-Cellular Therapies Inc. position peaked at $375K in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Avantax Advisory Services's 13F filing for Q1 2025, filed 6 May 2025.